Filed - Glenmark

India Formulations
Current Status
Value growth of over 21% vis-à-vis IPM which grew at 16.2% (April – Sept
06, ORG-IMS Sept 06)
Ranked #2 in dermatology (after GSK), strong presence in over 10
segments including female healthcare, paediatrics, respiratory, antiinfectives,
cardiovascular, diabetology, oncology
Increased focus on chronic lifestyle diseases
Launched 17 new products and novel combinations in the first half of the
year
Created 7 retail divisions, 1 institutional division & 1 targeting family
physicians for improved focus
Grew field force (currently 1850 medical representatives) and increased
focus on productivity improvements
Driving supply chain cost down; new plant at Baddi for tax-efficiencies fully
on-stream
Commenced in-licensing and co-marketing tie-ups for novel products
21